Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646303 | 0.91 | ALDH1A1 (0.64) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL16749906 | 0.86 | NOTUM (0.63) | NOTUMALDH1A1HPGDMAPTCYP11B1 | |
| SCHEMBL8569935 | 0.86 | NOTUM (0.63) | NOTUMALDH1A1HPGDMAPTCYP11B1 | |
| SCHEMBL9181801 | 0.84 | KDM4E (0.57) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL8813839 | 0.82 | NOTUM (0.58) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL28204772 | 0.82 | ALDH1A1 (0.49) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL20476397 | 0.81 | CASP3 (0.51) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL26079789 | 0.80 | NOTUM (0.54) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL1467859 | 0.80 | MEN1 (0.48) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL12194132 | 0.80 | HPGD (0.64) | ALDH1A1HPGDMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394251-B2 | Silodosin intermediate and preparation method therefor | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2016-07-19 | — | — | US | disclosed |
| US-20150148548-A1 | Silodosin Intermediate and Preparation Method Therefor | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. | 2015-05-28 | — | — | US | disclosed |
| EP-0799226-B1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-5972951-A | Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0799226-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019477-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148548-A1 | Silodosin Intermediate and Preparation Method Therefor | CYP51A1, VIP, CYP4F11 | NOTUM 128/4885ALDH1A1 539/4885HPGD 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.